CME/CE

Faculty: Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE Faculty: Kimberly D. Orleck, PA-C Presented at the 21st Annual Women’s Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on distinguishing IBS-C from IBS-D. Faculty explore the burden of disease, stigma, and the importance of a positive diagnostic strategy us...

Faculty: Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE Faculty: Kimberly D. Orleck, PA-C Presented at the 21st Annual Women’s Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on distinguishing IBS-C from IBS-D. Faculty explore the burden of disease, stigma, and the importance of a positive diagnostic strategy us...

Faculty: Alison Kole Faculty: Ghada Bourjeily, MD, FCCP Faculty: Rashmi Nisha Aurora, MD Faculty: Audrey Wells, MD This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA t...

Faculty: Alison Kole Faculty: Ghada Bourjeily, MD, FCCP Faculty: Rashmi Nisha Aurora, MD Faculty: Audrey Wells, MD This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA t...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoti...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoti...

Host: An De Vriese, MD, PhD Faculty: Muh Geot Wong, MBBS, PhD Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline ap...

Host: An De Vriese, MD, PhD Faculty: Muh Geot Wong, MBBS, PhD Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline ap...

Faculty: John McMurray, MD Faculty: Scott Solomon, MD Join Drs. Scott Solomon and John McMurray as they examine the new indication for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in treating patients with heart failure with LVEF ≥40%. Drawing on data from the FINEARTS-HF trial, faculty discuss patient selection, dosing considerations based on renal function, and the additive...

Faculty: James M. Cleary, MD, PhD This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with...

Faculty: James M. Cleary, MD, PhD This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with...